drugset / Trial / NCT07669779
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.
Timeline
- Start
- 2026-07-10
- Primary completion
- 2027-08-30
- Completion
- 2029-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK146D1 | Unknown | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Subject | Osimertinib | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |